Globeflex Capital L P Purchases Shares of 145,917 Xeris Biopharma Holdings, Inc. $XERS

Globeflex Capital L P purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 145,917 shares of the company’s stock, valued at approximately $1,156,000.

Other hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC boosted its stake in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the period. Goldman Sachs Group Inc. boosted its stake in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP acquired a new position in Xeris Biopharma in the 1st quarter valued at $170,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Stock Performance

XERS opened at $8.74 on Tuesday. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $10.08. The firm has a market cap of $1.59 billion, a P/E ratio of -79.45 and a beta of 0.66. The business’s fifty day moving average is $8.15 and its 200-day moving average is $6.88.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the transaction, the director directly owned 126,500 shares of the company’s stock, valued at $770,385. This trade represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00. Following the transaction, the insider owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. This represents a 1.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 271,499 shares of company stock worth $2,038,917. Corporate insiders own 4.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on XERS. Barclays lifted their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Xeris Biopharma currently has a consensus rating of “Hold” and a consensus target price of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.